Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2021.1915126
Abstract: ABSTRACT Introduction: Cholangiocarcinomas (CCAs) are rare and heterogeneous malignancies associated with poor prognosis, with most of the patients presenting with advanced disease at diagnosis. The recent advent of molecular profiling has led to the identification… read more here.
Keywords: idh mutant; mutant cholangiocarcinoma; idh; ivosidenib idh ... See more keywords
Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct026
Abstract: Background: LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalently at a novel binding site, enabling continued potency in preclinical models in the setting of second site IDH resistance… read more here.
Keywords: inhibitor; idh2; prior venetoclax; venetoclax prior ... See more keywords